Future Outlooks in the Treatment of R/R DLBCL
Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Read More
Additional Data Updates from ASH 2023
Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.
Read More
Treatment Sequencing of Later Line Therapies in R/R DLBCL
With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.
Read More
R/R DLBCL: Safety Considerations for Bispecific Antibodies
A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.
Read More
Bispecifics for Third Line Therapy of R/R DLBCL
Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
Read More
Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting
Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.
Read More
Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL
Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.
Read More
Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma
Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.
Read More
Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL
Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.
Read More
Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL
Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.
Read More
Tafasitamab and Lenalidomide for R/R DLBCL
A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.
Read More
Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
Read More
Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma
Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.
Read More
Concluding Thoughts on the DLBCL Treatment Landscape
DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Read More
Use of CAR T-Cell Therapies in Earlier Lines of DLBCL
Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.
Read More
Real-World Data With CAR-T Therapies in R/R DLBCL
Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.
Read More
Safety With CAR-T Therapies in R/R DLBCL
Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.
Read More
Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma
Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.
Read More
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.
Read More